Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
about
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitroIn vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneIn vitro activity of PD 127,391, an enhanced-spectrum quinoloneCiprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureusTreatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combinationInferring dynamic signatures of microbes in complex host ecosystemsChemotherapeuticsBactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.Studies on the antimicrobial properties of N-acylated ciprofloxacins.Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacinPenetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis.Detection of novel mutations in the gyrA gene of Staphylococcus aureus by nonradioisotopic single-strand conformation polymorphism analysis and direct DNA sequencing.In vitro antibiotic resistance in bacterial keratitis in London.Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.Ecotoxicological effects of ciprofloxacin on freshwater species: data integration and derivation of toxicity thresholds for risk assessment.Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infectionsIn vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.Isolation and characterization of Faecalibacterium prausnitzii from calves and piglets.Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacinOral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgeryOral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice.Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophiliaCiprofloxacin activity in cyst fluid from polycystic kidneys.Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocciTreatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin.Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infectionsRelationships between renal function and disposition of oral ciprofloxacinEvaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriersPharmacokinetics of ciprofloxacin after oral and parenteral administration.Comparative activity of ciprofloxacin against anaerobic bacteria.Open, prospective study of the clinical efficacy of ciprofloxacin.Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locationsPharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora
P2860
Q24670241-7995D515-8237-4DBD-AB61-C6E220DDDE8CQ24685787-99CCB5F8-9C2E-403C-9726-3D50B0062AB5Q28361070-B0BF6A59-044C-4158-AF96-7EE77586E899Q28361123-F935B192-B1DA-45E3-A5B5-51339FBC9154Q28361860-B2631AA5-CF30-4A38-81CF-A4DF82C178BDQ28481774-C2CFE30D-11BA-4ABD-A8FA-3E11F0370B12Q30047670-D92C7C36-BC57-4239-9586-04E3010E7ADFQ30451758-CCDA3D37-C1CB-460A-A03F-E8149D7D7DEDQ31096940-2F3490A0-EADB-4D6C-89ED-64435D707CFBQ33739836-474BD003-B9B3-49BE-8CD5-F5F46DDF1960Q33740832-7F66D63A-6720-4237-9963-627539ECA307Q33750373-99608ED3-1A3B-4B7D-906E-BD658E605267Q33954673-B4B5DA9B-870A-4C5A-A9C5-27182E0D8636Q33976236-2256ABDD-4147-4300-8119-C744F725AE2EQ34177747-81C426DA-9DE4-4424-9CA2-4E10D0AB7831Q34233075-6764FF11-CCFC-4BDC-9387-2132F3DAC32FQ34622742-8E4C2D99-BB10-4E70-A1F6-B3DA54B01441Q34796620-8C77953F-B4E9-41D9-86AD-14102637E9FBQ35136593-9D4117EF-8D03-4540-B2DD-DE36D66B8082Q35243584-AF9A46AC-5B21-4F52-911B-004FBBD33090Q35243870-FA5110EF-633F-426A-AD6F-CD3B463603F3Q35245500-1229D22C-FAF2-4436-8715-3C2EF1F15C69Q35248719-F156D4E8-6546-4FF5-8906-6253BC682334Q35248737-38E6EB58-3419-4632-A1F0-F421582B8C5CQ35250995-BE2B6867-C36E-4C0A-99D9-314D105B82D5Q35288542-BFA2FE57-78E4-4B2B-A73D-543E8D0FE916Q35306777-1F50BC20-C5F8-498E-BFFE-22359F387699Q35308712-3CB662FC-7D01-4880-A26C-01DFA73F24FEQ35361659-23919219-6D9E-442B-9732-870B9745ACA4Q35536186-5932C2A5-94B1-4E39-8E75-C4BAC9B2C231Q35539176-40A099F3-A005-4DF6-9E00-E80EAB6FDE10Q35539396-3FEB26A9-3B45-4B39-B038-B0432232B797Q35563727-C199D16E-2163-49E7-8C11-43F4D97E4AECQ35564482-1C8C551D-69D4-4594-BA93-F3C14B76DDBEQ35564821-B5276FD3-7342-4E5C-8ED8-A7FC45D5AD5CQ35570646-F544CFB3-7E01-4008-ACA5-5D2FA2B0FB5DQ35570963-8293FE1E-7833-4573-99BA-BCA703245BF1Q35571702-6FE556E9-CA12-41A6-A6F9-7FB3F7FFB0EFQ35572334-2F7BBB51-5E37-4203-8D23-13E90B856172Q35573482-C23091A8-632C-4698-9B23-E1CF7CBF2D63
P2860
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@ast
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@en
type
label
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@ast
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@en
prefLabel
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@ast
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@en
P2860
P356
P1476
Ciprofloxacin, a quinolone car ...... erobic and anaerobic bacteria.
@en
P2860
P304
P356
10.1128/AAC.25.3.319
P407
P577
1984-03-01T00:00:00Z